Cytosorbents Corp CTSO
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2005-06-17 |
| Shares Out. | 62,840,000 |
| Website | cytosorbents.com/ ↗ |
| Phone | 18008998648 |
| Employees | 129 |
| Revenue | $8.9M |
| Gross Profit | $6.1M |
| Net Income | -$5.1M |
| Free Cash Flow | -$10.2M |
| Total Assets | $40.6M |
| Total Liabilities | $38.4M |
| Equity | $2.2M |
About Cytosorbents Corp
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Cytosorbents Corp is a publicly traded company under the ticker symbol CTSO on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)